Paper Titles
Supercritical Carbon Dioxide Assisted Impregnation of Molsidomine into Poly(DL-Lactide-co-Glycolide) for Sustained Release Applications
p.501
Release Profile of a Model Protein Drug Depending on the Stability of Microspheres Based on Polyelectrolyte Complex
p.505
All-Trans Retinoic Acid (atRA) Release from atRA-Loaded Folate-Poly(Ethylene Glycol)/Polyethylenimine Nanoparticles for Folate-Mediated Tumor Targeting
p.509
The Double-Layered Microsphere: Encapsulation of Water-Soluble Protein with PLGA
p.513
Controlled Angiogenic Factor Release from Alginate Gels
p.517
Synthesis and Characterization of Polyethylenimine-Graft-Poly(L-Lactide-Co-Glycolide) Block Copolymers for Gene Delivery
p.521
A Novel Degradation Controlled Hyaluronic Acid Derivatives
p.525
A Novel Branch-Type PEGylation of Aptamer Therapeutics
p.529
The Study of Antibiotic Drug-Loaded Polymer Films for the Prevention of the Infection of External Fixation Devices
p.533

Controlled Angiogenic Factor Release from Alginate Gels

Article Preview

Abstract:

Therapeutic angiogenesis by localized delivery of angiogenic factors is a promising approach to treat patients with cardiovascular disease and to engineer large tissues. Vascular endothelial growth factor (VEGF) is the most common and biologically active form of the VEGF family, which acts as a mitogen to endothelial cells and is capable of specific binding to heparin. However, when VEGF is administered via bolus injection, it can be widely distributed, and its concentration is likely to be within the effective window for only a short time period due to rapid degradation. Delivery of angiogenic factors, using controlled drug delivery strategies, offers great potential to promote angiogenesis at a specific site while reducing the unwanted side effects that may occur with systemic delivery. We now report on the sustained release of VEGF from alginate gels, modified with a heparin-binding peptide. Briefly, a small peptide with the sequence of G5K(βA)FAKLAARLYRKA, which is known to specifically interact with heparin, was chemically conjugated to alginate, and the peptide-modified alginate formed gels after mixing with heparin and VEGF. The release rate of VEGF from the gels slowed in vitro for over 45 days, compared with release from non-modified alginate gels. This result suggests potential applications of alginate gels in promoting angiogenesis for therapeutic purposes, as well as for tissue engineering.

You might also be interested in these eBooks
Advanced Biomaterials VII View Preview

Info:

Periodical:

Key Engineering Materials (Volumes 342-343)

Pages:

517-520

DOI:

https://doi.org/10.4028/www.scientific.net/KEM.342-343.517

Citation:

Cite this paper

Online since:

July 2007

Authors:

Kuen Yong Lee, Naoki Nishishita, Yoshiaki Hirano, David Mooney

Keywords:

Alginate Gel, Angiogenic Factor, Heparin-Binding Peptide, Sustained Release

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

© 2007 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

References

[1] M.J. Post, R. Laham, F.W. Selleke and M. Simons: Cardiovas Res Vol. 49 (2001), p.522.

Google Scholar

[2] D.J. Mooney and A.G. Mikos: Sci Am Vol. 280 (1999), p.60.

Google Scholar

[3] G. Neufeld, T. Cohen, S. Gengrinovitch and Z. Poltorak: FASEB J Vol. 13 (1999), p.9.

Google Scholar

[4] K.Y. Lee, M.C. Peters and D.J. Mooney: J Controlled Rel Vol. 87 (2003), p.49.

Google Scholar

[5] J. Folkman and Y. Shing: Adv Exp Med Biol Vol. 313 (1992), p.355.

Google Scholar

[6] D. Godspodarowicz and J. Cheng: J Cell Physiol Vol. 128 (1986), p.475.

Google Scholar

[7] S.E. Sakiyama, J.C. Schense and J.A. Hubbell: FASEB J Vol. 13 (1999), p.2214.

Google Scholar

[8] D.B. Pike, S. Cai, K.R. Pomraning, M.A. Firpo, R.J. Fisher, X.Z. Shu, G.D. Prestwich and R.A. Peatti: Biomaterials Vol. 27 (2006), p.5242.

Google Scholar

[9] P.J. Groves, R.P. Shellis and P.A. Dieppe: Anal Chem Vol. 245 (1997), p.247.

Google Scholar